Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;3(8):e559.
doi: 10.1016/S2666-5247(22)00120-3. Epub 2022 May 27.

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients

Grégory Destras  1 , Antonin Bal  1 , Bruno Simon  2 , Bruno Lina  1 , Laurence Josset  3
Affiliations

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients

Grégory Destras et al. Lancet Microbe. 2022 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

GD, AB, and BS contributed equally. We declare no competing interests.

References

    1. Rockett R, Basile K, Maddocks S, et al. Resistance mutations in SARS-CoV-2 delta variant after sotrovimab use. N Engl J Med. 2022;386:1477–1479. - PMC - PubMed
    1. Cathcart AL, Havenar-Daughton C, Lempp FA, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. 2022 doi: 10.1101/2021.03.09.434607. published online Feb 18. (preprint). - DOI
    1. Bruel T, Hadjadj J, Maes P, et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med. 2022 doi: 10.1038/s41591-022-01792-5. published online March 23. - DOI - PubMed
    1. Bal A, Simon B, Destras G, et al. Detection and prevalence of SARS-CoV-2 co-infections during the Omicron variant circulation, France, December 2021–February 2022. medRxiv. 2022 doi: 10.1101/2022.03.24.22272871. published online March 27. (preprint). - DOI - PMC - PubMed
    1. Destras G, Assaad S, Bal A, et al. Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19. Lancet Microbe. 2021;2:e424. - PMC - PubMed

Supplementary concepts